Scholars Central

Review articlePublished 21 Jul 2016

Biomarkers for drug-induced liver injury

Authors: Paul B Watkins

Clinical Practice

Volume 7 · Issue 4 · Pages 367

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

New biomarkers are needed in the clinic to distinguish drug-induced liver injury from other types of liver injuries, and to identify which specific drug is the culprit when drug-induced liver injury occurs in the setting of polypharmacy. There is also a need for new biomarkers that can be used in clinical trials to identify which new drugs in development have serious liver liabilities. When there are few alternative therapies available, biomarkers are needed to be able to identify patients susceptible to drug-induced liver injury from drugs known to have this liability. Developing and validating such biomarkers will require the establishment of well-annotated serum and urine banks from prospective clinical trials of drugs that have serious liver safety liabilities as well as those that do not.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Practice.

All its articles

Article · 28 Mar 2025

Using

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Practice
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Paul B Watkins”